Home Featured Page 53

Featured

Latest

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits of Psychedelic Therapy

Why Ketamine Is Changing Psychiatry

Trump’s Psychedelics Executive Order: Reactions From Across the Field and Beyond

Pinco Güncel Giriş Şifrənizi Yeniləmənin Əhəmiyyəti

Vital 4: Informational Session and Q+A, with Diego

Vital 4: Informational Session and Q+A, with Johanna

Jungian Psychology, Psychedelics, and the Multiplicity of Self

Psychedelic Funding Update: Q2 2024

What is Spiritual Emergence and How Does it Relate to Psychedelics?

Exploring the Fungal Kingdom: Cultivation, Connection, and the Potential of Permaculture

Pα+ Psychedelic Bulletin #169: Brin Backs Soneira, But Patent Questions Loom...

Psychedelics in Palliative Care: Screening, Safety Measures, and Experiences With the...

When Data Meets Doubt: Investigating the FDA Panel’s Rejection of MDMA

Psychedelic Research: The Current Landscape and Future Directions

EDITOR PICKS

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits...

Why Ketamine Is Changing Psychiatry

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits of Psychedelic Therapy

Why Ketamine Is Changing Psychiatry

Trump’s Psychedelics Executive Order: Reactions From Across the Field and Beyond

Pinco Güncel Giriş Şifrənizi Yeniləmənin Əhəmiyyəti

Vital 4: Informational Session and Q+A, with Diego

Vital 4: Informational Session and Q+A, with Johanna

Jungian Psychology, Psychedelics, and the Multiplicity of Self

Psychedelic Funding Update: Q2 2024

What is Spiritual Emergence and How Does it Relate to Psychedelics?

Exploring the Fungal Kingdom: Cultivation, Connection, and the Potential of Permaculture

Pα+ Psychedelic Bulletin #169: Brin Backs Soneira, But Patent Questions Loom...

Psychedelics in Palliative Care: Screening, Safety Measures, and Experiences With the...

When Data Meets Doubt: Investigating the FDA Panel’s Rejection of MDMA

Psychedelic Research: The Current Landscape and Future Directions

EDITOR PICKS

Breaking: FDA Awards Priority Review Vouchers to Otsuka, Compass, and Usona

Erica Rex: Seeing What Is There, Trauma, Integration, and the Limits...

Why Ketamine Is Changing Psychiatry

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY